title: Pharmaceutical Approval Update.
abstract: Lesinurad (Zurampic) for gout-related hyperuricemia; selexipag (Uptravi) for pulmonary arterial hypertension; sugammadex (Bridion) to reverse neuromuscular blockade after surgery; and alectinib (Alecensa) for lung cancer.
authors.forename: Chris
authors.initials: C
authors.lastname: Fellner